Regulatory Watch
June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022 June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022

Contact Us

We read every message. Response times vary based on volume, but we aim to reply within 48 hours for substantive inquiries.

General Inquiries

Questions about the site, our methodology, or general feedback:
hello@peptideexaminer.com

Tips & Corrections

Have information about a vendor, regulatory action, or factual error in our content? We investigate all credible tips and issue corrections promptly when warranted.
tips@peptideexaminer.com

Ethics & Editorial

Concerns about editorial independence, conflicts of interest, or ethical matters:
ethics@peptideexaminer.com

What We Cannot Help With

  • Medical advice or treatment recommendations
  • Vendor recommendations or "which vendor should I use" questions
  • Sourcing peptides or connecting you with suppliers
  • Legal advice about peptide possession or use

We're an analysis platform, not a medical practice or marketplace. For health questions, consult a licensed healthcare provider.